History

Aesica is a fast-growing UK company with a global footprint.

March 2011

Aesica completes the acquisition of 3 sites from UCB in Germany and Italy and expands formulated product development and manufacturing capabilities.

February 2011

Aesica ranks number three in the Sunday Times Deloitte Buyout Track 100 for 2011, by increasing profit by 106% per year.

January 2011

R5, Formulation Development announces significant expansion as it starts construction of a new analytical chemistry laboratory.

August 2010

Aesica invests in a new high containment facility.

July 2010

Aesica continues US expansion through recruitment of a Business Development Team on the East and West Coast.

June 2010

Aesica acquires formulation development and clinical trial manufacturing company, R5 Pharmaceuticals, Nottingham, UK

February 2010

Aesica ranks number forty-nine in the Sunday Times Deloitte Buyout Track 100 for 2010.

September 2007

Aesica acquires secondary manufacturing facility from Abbott at Queenborough, Kent, UK.

August 2007

Aesica opens new API pilot plant at Cramlington site.

October 2006

Aesica acquires chemical manufacturing facility from MSD at Ponders End, Enfield, UK.

2004-2006

Aesica established as the partner of choice for global pharmaceutical companies.

September 2004

Aesica completes management buyout from BASF’s Cramlington site.  The deal was funded by LDC, the private equity arm of Lloyds TSB Group.

2003

Opening of new API technical centre at Cramlington site.

1995

BASF acquired Boots Pharmaceuticals.

1987

Second manufacturing plant commissioned for development.

1983

First manufacturing plant commissioned for development.

1977

Cramlington site purchased by Boots Pharmaceuticals